Saga Y - Search Results

1

Forced Vasohibin-1 Expression Increases Paclitaxel Sensitivity of Ovarian Cancer by Inhibiting Microtubule Activity.

Koyanagi T, Saga Y, Takahashi Y, Tamura K, Takahashi S, Taneichi A, Takei Y, Mizukami H, Fujiwara H. Koyanagi T, et al. Among authors: saga y. Cancer Rep (Hoboken). 2024 Dec;7(12):e70100. doi: 10.1002/cnr2.70100. Cancer Rep (Hoboken). 2024. PMID: 39710372 Free PMC article.

2

In vivo delivery of siRNA targeting vasohibin-2 decreases tumor angiogenesis and suppresses tumor growth in ovarian cancer.

Koyanagi T, Suzuki Y, Saga Y, Machida S, Takei Y, Fujiwara H, Suzuki M, Sato Y. Koyanagi T, et al. Among authors: saga y. Cancer Sci. 2013 Dec;104(12):1705-10. doi: 10.1111/cas.12297. Epub 2013 Nov 8. Cancer Sci. 2013. PMID: 24118388 Free PMC article.

3

The angiogenesis regulator vasohibin-1 inhibits ovarian cancer growth and peritoneal dissemination and prolongs host survival.

Takahashi Y, Saga Y, Koyanagi T, Takei Y, Machida S, Taneichi A, Mizukami H, Sato Y, Matsubara S, Fujiwara H. Takahashi Y, et al. Among authors: saga y. Int J Oncol. 2015 Dec;47(6):2057-63. doi: 10.3892/ijo.2015.3193. Epub 2015 Oct 8. Int J Oncol. 2015. PMID: 26460696 Free PMC article.

4

Vasohibin-1 expression inhibits advancement of ovarian cancer producing various angiogenic factors.

Takahashi Y, Saga Y, Koyanagi T, Takei Y, Machida S, Taneichi A, Mizukami H, Sato Y, Matsubara S, Fujiwara H. Takahashi Y, et al. Among authors: saga y. Cancer Sci. 2016 May;107(5):629-37. doi: 10.1111/cas.12911. Epub 2016 Mar 30. Cancer Sci. 2016. PMID: 26893100 Free PMC article.

5

Targeting human vasohibin-2 by a neutralizing monoclonal antibody for anti-cancer treatment.

Koyanagi T, Suzuki Y, Komori K, Saga Y, Matsubara S, Fujiwara H, Sato Y. Koyanagi T, et al. Among authors: saga y. Cancer Sci. 2017 Mar;108(3):512-519. doi: 10.1111/cas.13149. Cancer Sci. 2017. PMID: 28032401 Free PMC article.

6

Knockout of vasohibin-2 reduces tubulin carboxypeptidase activity and increases paclitaxel sensitivity in ovarian cancer.

Koyanagi T, Saga Y, Takahashi Y, Tamura K, Yoshiba T, Takahashi S, Taneichi A, Takei Y, Urabe M, Mizukami H, Fujiwara H. Koyanagi T, et al. Among authors: saga y. Cancer Med. 2021 Apr;10(8):2732-2739. doi: 10.1002/cam4.3841. Epub 2021 Mar 12. Cancer Med. 2021. PMID: 33710778 Free PMC article.

7

The role of non-genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death.

Koyanagi T, Saga Y, Takahashi Y, Tamura K, Yoshiba T, Takahashi S, Taneichi A, Takei Y, Mizukami H, Fujiwara H. Koyanagi T, et al. Among authors: saga y. Cancer Rep (Hoboken). 2024 Jan;7(1):e1934. doi: 10.1002/cnr2.1934. Epub 2023 Nov 27. Cancer Rep (Hoboken). 2024. PMID: 38013666 Free PMC article.

8

Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells.

Saga Y, Mizukami H, Suzuki M, Kohno T, Urabe M, Ozawa K, Sato I. Saga Y, et al. Clin Cancer Res. 2002 May;8(5):1248-52. Clin Cancer Res. 2002. PMID: 12006545

9

A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer.

Takei Y, Suzuki M, Ohwada M, Saga Y, Kohno T, Machida S, Sato I. Takei Y, et al. Among authors: saga y. Oncol Rep. 2003 Jul-Aug;10(4):951-5. Oncol Rep. 2003. PMID: 12792751 Clinical Trial.

10

Overexpression of thymidylate synthase mediates desensitization for 5-fluorouracil of tumor cells.

Saga Y, Suzuki M, Mizukami H, Kohno T, Takei Y, Fukushima M, Ozawa K. Saga Y, et al. Int J Cancer. 2003 Sep 1;106(3):324-6. doi: 10.1002/ijc.11221. Int J Cancer. 2003. PMID: 12845668

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

468 results

Search Page

Filters